Alpha Profiles · Company Profile

Protalix BioTherapeutics, Inc.

Canonical company identity and public leadership record.

https://registry.alpha.ac/companies/protalix-biotherapeutics-inc

Entity: Public listing published
Primary listing: NYSE: PLX
Verification: Partially verified
Last reviewed: 2026-09-05T21:32:02.569929+00:00

Overview

Alpha's canonical identity and public leadership record for Protalix BioTherapeutics, Inc..

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

4 public records

Dror Bashan

President and Chief Executive Officer

State: confirmed
Effective: From Apr 30, 2026
Confidence: 94%
Evidence: PLX DEF 14A executive officersApr 30, 2026

Eyal Rubin

Senior Vice President and Chief Financial Officer

State: confirmed
Effective: From Apr 30, 2026
Confidence: 94%
Evidence: PLX DEF 14A executive officersApr 30, 2026

Gilad Mamlok

Senior Vice President, Chief Financial Officer, Treasurer and Secretary

State: confirmed
Effective: From Apr 30, 2026
Confidence: 94%
Evidence: PLX DEF 14A executive officersApr 30, 2026

Yaron Naos

Senior Vice President, Chief Operating Officer

State: confirmed
Effective: From Apr 30, 2026
Confidence: 94%
Evidence: PLX DEF 14A executive officersApr 30, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 5, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.